Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Stimulator of interferon genes (STING) is an innate immune signaling protein critical to
infections, autoimmunity, and cancer. STING signaling is also emerging as an exciting and …

Recent clinical trials have highlighted the limited efficacy of T cell–based immunotherapy in
patients with glioblastoma (GBM). To better understand the characteristics of tumor …

Triple‐negative breast cancer has an immunologically “cold” microenvironment, which leads
to resistance to current immunotherapy. The activation of stimulator of interferon genes …

Background Glioblastoma is a highly aggressive brain cancer that is resistant to
conventional immunotherapy strategies. Botensilimab, an Fc-enhanced anti-CTLA-4 …

Purpose: Patients with glioblastoma (GBM) have a dismal prognosis. Although the DNA
alkylating agent temozolomide (TMZ) is the mainstay of chemotherapy, therapeutic …

Tumor-derived extracellular vesicles (EVs) are one of the most important ways of
intercellular communication and signaling. Cancer stem cells (CSCs) secrete EVs to …

Enhancing the efficacy of glioma treatment poses a significant challenge. Ferroelectric
nanomaterials, renowned for their remarkable piezoelectric properties, generate reactive …

Nuclear factor kappa B (NFκB) is a pathogenic factor in chronic lymphocytic leukemia (CLL)
that is not addressed specifically by current therapies. NFκB is activated by inflammatory …

Immune checkpoint blockade (ICB) therapy has improved treatment effects in multiple
cancers. Gene mutations in the DNA damage repair pathway (DDR) may cause genomic …